Principal Financial Group Inc. Sells 11,064 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Principal Financial Group Inc. cut its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 4.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 214,353 shares of the biotechnology company’s stock after selling 11,064 shares during the period. Principal Financial Group Inc. owned approximately 0.43% of REGENXBIO worth $2,249,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of RGNX. Redmile Group LLC boosted its holdings in REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock worth $51,327,000 after buying an additional 323,100 shares during the period. Geode Capital Management LLC raised its position in REGENXBIO by 4.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company’s stock valued at $11,422,000 after purchasing an additional 44,037 shares in the last quarter. Integral Health Asset Management LLC increased its position in REGENXBIO by 25.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after purchasing an additional 190,000 shares during the period. Charles Schwab Investment Management Inc. boosted its position in REGENXBIO by 9.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock valued at $4,382,000 after acquiring an additional 37,055 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in REGENXBIO by 9.3% in the second quarter. Bank of New York Mellon Corp now owns 339,514 shares of the biotechnology company’s stock worth $3,972,000 after purchasing an additional 28,846 shares in the last quarter. 88.08% of the stock is owned by institutional investors.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX opened at $7.77 on Friday. REGENXBIO Inc. has a one year low of $7.14 and a one year high of $28.80. The business’s fifty day moving average price is $9.07 and its two-hundred day moving average price is $10.79. The stock has a market cap of $384.96 million, a PE ratio of -1.54 and a beta of 1.24.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Morgan Stanley reissued an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. HC Wainwright decreased their price objective on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 price target on shares of REGENXBIO in a research note on Wednesday, December 11th. Finally, Raymond James restated an “outperform” rating and issued a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and an average target price of $35.27.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.